M
M. Sydenham
Researcher at Institute of Cancer Research
Publications - 34
Citations - 6413
M. Sydenham is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Radiation therapy & Breast cancer. The author has an hindex of 19, co-authored 31 publications receiving 5068 citations.
Papers
More filters
Journal ArticleDOI
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
Christopher M. Nutting,Christopher M. Nutting,James P Morden,Kevin J. Harrington,Kevin J. Harrington,Teresa Guerrero Urbano,Shreerang Bhide,Catharine H. Clark,Elizabeth Miles,Aisha Miah,Kate Newbold,Mary Anne Lagmay Tanay,Fawzi Adab,Sarah Jefferies,Christopher D Scrase,Beng K. Yap,Roger A'Hern,M. Sydenham,M. Emson,Emma Hall +19 more
TL;DR: Sparing the parotid glands with IMRT significantly reduces the incidence of xerostomia and leads to recovery of saliva secretion and improvements in associated quality of life, and thus strongly supports a role for IMRT in squamous-cell carcinoma of the head and neck.
Journal ArticleDOI
The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.
Søren M. Bentzen,R.K. Agrawal,Edwin Aird,Barrett Jm,Peter Barrett-Lee,Judith M Bliss,Julia Brown,John Dewar,Dobbs Hj,Joanne S Haviland,Peter Hoskin,Penelope Hopwood,Lawton Pa,B. Magee,J. Mills,Morgan Da,Owen,Simmons S,Georges Sumo,M. Sydenham,K Venables,Yarnold +21 more
TL;DR: A radiation schedule delivering 40 Gy in 15 fractions seems to offer rates of local-regional tumour relapse and late adverse effects at least as favourable as the standard schedule of 50 Gy in 25 fractions.
Journal ArticleDOI
The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials
Joanne S Haviland,Joanne S Haviland,J Roger Owen,John Dewar,R.K. Agrawal,Jane Barrett,Peter Barrett-Lee,H Jane Dobbs,Penelope Hopwood,Lawton Pa,Brian J Magee,J. Mills,Simmons S,M. Sydenham,K Venables,Judith M Bliss,John Yarnold,John Yarnold +17 more
TL;DR: The UK Standardisation of Breast Radiotherapy (START) trial as mentioned in this paper showed that lower total doses of radiotherapy delivered in fewer, larger doses (fractions) are at least as safe and effective as the historical standard regimen (50 Gy in 25 fractions) for women after primary surgery for early breast cancer.
Journal ArticleDOI
The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.
Søren M. Bentzen,R.K. Agrawal,Edwin Aird,Barrett Jm,Peter Barrett-Lee,Judith M Bliss,Julia Brown,John Dewar,Dobbs Hj,Joanne S Haviland,Peter Hoskin,Penelope Hopwood,Lawton Pa,B. Magee,J. Mills,Morgan Da,Owen,Simmons S,Georges Sumo,M. Sydenham,K Venables,Yarnold +21 more
TL;DR: The data are consistent with the hypothesis that breast cancer and the dose-limiting normal tissues respond similarly to change in radiotherapy fraction size, and could offer similar rates of tumour control and normal tissue damage as the international standard fractionation schedule.
Journal ArticleDOI
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
A.M. Brunt,A.M. Brunt,Joanne S Haviland,Duncan Wheatley,Mark A Sydenham,Abdulla Alhasso,David J Bloomfield,Charlie Chan,Mark Churn,Susan Cleator,Charlotte E. Coles,Andrew Goodman,Adrian Harnett,Penelope Hopwood,Anna M. Kirby,Cliona C. Kirwan,Carolyn Morris,Zohal Nabi,Elinor J. Sawyer,Navita Somaiah,Liba Stones,Isabel Syndikus,Judith M Bliss,John Yarnold,Anne C Armstrong,Judith Bliss,D. Bloomfield,Jo Bowen,Murray Brunt,Hannah Chantler,C. Coles,Ellen M. Donovan,Andy Goodman,Susan Griffin,Jo Haviland,Penny Hopwood,Anna Kirby,Julie Kirk,C C Kirwan,Marjory MacLennan,Mark Sculphur,Judith Sinclair,M. Sydenham,Jean Tremlett,K Venables,Duncan Wheatley,J.R. Yarnold +46 more
TL;DR: 26 Gy in five fractions over 1 week is non-inferior to the standard of 40 Gy in 15 fractions over 3 weeks for local tumour control, and is as safe in terms of normal tissue effects up to 5 years for patients prescribed adjuvant local radiotherapy after primary surgery for early-stage breast cancer.